Меню
Идёт набор NCT05937789

Early Vitamin D3 Supplementation for Critically Ill Patients

Без фазы С лечением Vitamin D Deficiency Critical Illness

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Vitamin D3, Medium Chain Triglycerides (MCT).
Кому может быть актуально
Состояния в реестре: Vitamin D Deficiency, Critical Illness. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Тайвань
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Effects of Early Vitamin D3 Supplementation on Clinical Outcomes for Critically Ill Patients

Обзор

There are no clear international guidelines for dosing vitamin D based on deficiency severity. Therefore, a new clinical trial is needed to evaluate the benefits of early vitamin D supplementation in maintaining sufficient levels for critically ill patients. The investigators conducted a multicenter clinical trial in Taiwan focusing on vitamin D and critically ill patients. 240 patients with low calcidiol levels will be enrolled and be provided varying supplementation doses to maintain their serum calcidiol levels ≥ 30 ng/mL within 30 days of ICU admission. The serum levels of calcidiol and PTH will be measured on Day 0, Day 7, Day 14 and Day 30 before and after vitamin D supplementation. The results will serve as a valuable reference for intensivists when formulating appropriate vitamin D treatment strategy to maximize clinical benefits for critically ill patients.

Подробное описание

Recent studies have highlighted a prevalent vitamin D deficiency in critically ill patients, ranging from 26% to 82%. These patients experience longer ICU stays, higher medical expenses, and increased sepsis-related mortality. The investigators conducted a multicenter clinical trial in Taiwan focusing on vitamin D and critically ill patients. In the first phase, the epidemiological investigation found significantly lower serum calcidiol levels of approximately 20.9 ng/mL compared to the normal range of 30-60 ng/mL in ICU patients. The second phase, a randomized control study, preliminarily demonstrated that supplementing 576,000 IU of vitamin D3 in critically ill patients with serum calcidiol levels below 20 ng/mL significantly reduced the risk of multidrug resistant bacterial infections within 30 days. An Austrian trial also showed that adequate vitamin D supplementation lowered in-hospital mortality in severely deficient patients. The importance of vitamin D supplementation for critically ill patients with vitamin D deficiency is evident, as their clinical prognosis is closely related to achieving adequate serum calcidiol levels. However, there are no clear international guidelines for dosing vitamin D based on deficiency severity. Therefore, a new clinical trial is needed to evaluate the benefits of early vitamin D supplementation in maintaining sufficient levels for critically ill patients. The investigators will enroll 240 patients with low calcidiol levels and provide varying supplementation doses to maintain their serum calcidiol levels ≥ 30 ng/mL within 30 days of ICU admission. The serum levels of calcidiol and PTH will be measured on Day 0, Day 7, Day 14 and Day 30 before and after vitamin D supplementation. The results will serve as a valuable reference for intensivists when formulating appropriate vitamin D treatment strategy to maximize clinical benefits for critically ill patients.

Вмешательства

  • Пищевая добавка Vitamin D3
    Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
  • Пищевая добавка Medium Chain Triglycerides (MCT)
    Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours

Первичные конечные точки

  • 30-day mortality rate [Срок оценки: 30 days]
Вторичные конечные точки (7)
  • 30-day mortality rate of patients who survives >7 days [Срок оценки: 30 days]
  • Length of ICU stay for surviving patients [Срок оценки: 30 days]
  • Length of hospital stay for surviving patients [Срок оценки: 30 days]
  • 30-day mortality based on serum 25(OH)D levels on day 7 [Срок оценки: 30 days]
  • 30-day mortality based on serum 25(OH)D levels on day 30 [Срок оценки: 30 days]
  • 30-day mortality based on APACHE II scores at ICU 24 hours [Срок оценки: 30 days]
  • Correlation of 25(OH)D increment after vitamin D supplement and body weight [Срок оценки: 7 days]

Критерии участия

Критерии включения

  • ≥18-year-old critically ill patient.
  • ICU admission < 24 hours.
  • Baseline 25(OH)D levels within 24 hours of ICU admission < 20 ng/mL.
  • Expected ICU length of stay ≥ 72 hours.

Критерии исключения

  • Hypercalcemia (ie. total serum calcium levels > 2.6 mmol/L).
  • Disorders affecting serum 25(OH)D levels, calcium metabolism, or bone metabolism (eg, parathyroid disease, rickets, or severe cirrhosis \[Child C\]).
  • Having received high-dose vitamin D3 therapy (ie. > 2,000 IU daily or a single dose of ≥ 10,000 IU) within the past four weeks.
  • Active COVID-19 at ICU admission.
  • Organ transplant.
  • Having had tuberculosis, sarcoidosis or kidney stones within the past year.
  • Having renal dialysis, continuous kidney replacement therapy (CKRT), acute kidney injury (AKI).
  • Having ICU admission within the past three months.
  • Non-native-speaking patients and their families
  • Pregnant women.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Четверное слепое
Основная цель
Лечение

Центры проведения

Тайвань · 1 центр
  • National Taiwan University Hospital — Taipei

Идентификаторы

NCT: NCT05937789 · 202305074RIPC

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗